Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Striving for synergy: how to improve cancer immunotherapy through multiple agonist costimulation.

Adler AJ, Vella AT.

Immunotherapy. 2013 Dec;5(12):1271-3. doi: 10.2217/imt.13.129. No abstract available.

PMID:
24283834
2.

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.

Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG.

J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec.

3.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

4.

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

Moran AE, Kovacsovics-Bankowski M, Weinberg AD.

Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14. Review.

5.

CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.

Lee SJ, Rossi RJ, Lee SK, Croft M, Kwon BS, Mittler RS, Vella AT.

J Immunol. 2007 Aug 15;179(4):2203-14.

6.

PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.

Chen M, Ouyang H, Zhou S, Li J, Ye Y.

Cell Immunol. 2014 Feb;287(2):91-9. doi: 10.1016/j.cellimm.2014.01.003. Epub 2014 Jan 13.

PMID:
24487032
7.

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Redmond WL, Linch SN, Kasiewicz MJ.

Cancer Immunol Res. 2014 Feb;2(2):142-53. doi: 10.1158/2326-6066.CIR-13-0031-T. Epub 2013 Nov 11.

8.

The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.

Lynch DH.

Immunol Rev. 2008 Apr;222:277-86. doi: 10.1111/j.1600-065X.2008.00621.x. Review.

PMID:
18364008
9.

Science gone translational: the OX40 agonist story.

Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD.

Immunol Rev. 2011 Nov;244(1):218-31. doi: 10.1111/j.1600-065X.2011.01069.x. Review.

10.

Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.

Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, Green MH, Tutt AL, Glennie MJ, Al-Shamkhani A.

Eur J Immunol. 2002 Dec;32(12):3617-27.

11.

Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients.

Baruah P, Lee M, Odutoye T, Williamson P, Hyde N, Kaski JC, Dumitriu IE.

Immunobiology. 2012 Jul;217(7):669-75. doi: 10.1016/j.imbio.2011.11.005. Epub 2011 Nov 22.

PMID:
22204816
12.

Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.

Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V, Rodriguez M, Aznar MA, Jure-Kunkel M, Melero I.

Eur J Immunol. 2016 Mar;46(3):513-22. doi: 10.1002/eji.201445388. Epub 2016 Feb 9. Review.

13.

Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.

Hombach AA, Abken H.

Immunotherapy. 2013 Jul;5(7):677-81. doi: 10.2217/imt.13.54. No abstract available.

PMID:
23829616
14.

High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.

Dumitriu IE, Baruah P, Finlayson CJ, Loftus IM, Antunes RF, Lim P, Bunce N, Kaski JC.

Circ Res. 2012 Mar 16;110(6):857-69. doi: 10.1161/CIRCRESAHA.111.261933. Epub 2012 Jan 26.

PMID:
22282196
15.

Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells.

Redmond WL, Linch SN.

Hum Vaccin Immunother. 2016 Oct 2;12(10):2519-2522. doi: 10.1080/21645515.2016.1193277. Epub 2016 Jul 26.

16.

4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.

Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB.

Immunology. 2004 Aug;112(4):559-66.

17.

4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy.

Choi BK, Lee SC, Lee MJ, Kim YH, Kim YW, Ryu KW, Lee JH, Shin SM, Lee SH, Suzuki S, Oh HS, Kim CH, Lee DG, Hwang SH, Yu EM, Lee IO, Kwon BS.

J Immunother. 2014 May;37(4):225-36. doi: 10.1097/CJI.0000000000000027.

PMID:
24714356
18.

Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.

Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, Evering W, Logronio K, Tu GH, Tsaparikos K, Li X, Wang H, Ying C, Xiong M, VanArsdale T, Lin JC.

Cancer Immunol Res. 2015 Feb;3(2):149-60. doi: 10.1158/2326-6066.CIR-14-0118. Epub 2014 Nov 11.

19.

The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.

Hombach AA, Holzinger A, Abken H.

Curr Mol Med. 2013 Aug;13(7):1079-88. Review.

PMID:
23116267
20.

Clinical deployment of antibodies for treatment of melanoma.

Curti BD, Urba WJ.

Mol Immunol. 2015 Oct;67(2 Pt A):18-27. doi: 10.1016/j.molimm.2015.01.025. Epub 2015 Mar 6. Review.

PMID:
25746916

Supplemental Content

Support Center